Dosage-dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c-Myc collaborating genes and p53 function

Blood

Volumn 121, Issue 11, 2013, Pages 2038-2050

  Heideman, Marinus R ^a   Wilting, Roel H ^a   Yanover, Eva ^a   Velds, Arno ^a   De Jong, Johann ^a   Kerkhoven, Ron M ^a   Jacobs, Heinz ^a   Wessels, Lodewyk F ^a   Dannenberg, Jan Hermen ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; PROTEIN P53; HDAC1 PROTEIN, MOUSE; HDAC2 PROTEIN, MOUSE; MYC PROTEIN; MYC PROTEIN, MOUSE;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME 15; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; FLOW CYTOMETRY; GAMMA IRRADIATION; HISTOPATHOLOGY; IN VIVO STUDY; LATENT PERIOD; LYMPHOMA CELL LINE; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SOUTHERN BLOTTING; T CELL LYMPHOMA; T-CELL LYMPHOMA CELL LINE; THYMOCYTE; THYMUS LYMPHOMA; TRISOMY; TUMOR CELL LINE; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL TRANSFORMATION; EPISTASIS; GENE; GENE DOSAGE; GENE EXPRESSION REGULATION; GENETICS; LYMPHOMA; METABOLISM; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; EPISTASIS, GENETIC; GENE DOSAGE; GENE EXPRESSION REGULATION; GENES; GENES, TUMOR SUPPRESSOR; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; LYMPHOMA; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS C-MYC; TUMOR SUPPRESSOR PROTEIN P53;

MLCS; MLOWN;

EID: 84877609321     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-08-450916     Document Type: Article

References (49)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
2. Hagelkruys A, Sawicka A, Rennmayr M, Seiser C. The biology of HDAC in cancer: the nuclear and epigenetic components. Handb Exp Pharmacol. 2011;(206):13-37.
3. Yang X-J, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol. 2008;9(3):206-218.
4. Gregoretti IV, Lee Y-M, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol. 2004;338(1):17-31.
5. Wilting RH, Yanover E, Heideman MR, et al. Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis. EMBO J. 2010;29(15):2586-2597.
6. Haberland M, Johnson A, Mokalled MH, et al. Genetic dissection of histone deacetylase requirement in tumor cells. 2009;106(19): 7751-7755.
7. Montgomery RL, Davis CA, Potthoff MJ, et al. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev. 2007;21(14):1790-1802.
8. Yamaguchi T, Cubizolles F, Zhang Y, et al. Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression. Genes Dev. 2010;24(5):455-469.
9. LeBoeuf M, Terrell A, Trivedi S, et al. Hdac1 and Hdac2 act redundantly to control p63 and p53 functions in epidermal progenitor cells. Dev Cell. 2010;19(6):807-818.
10. Ma P, Pan H, Montgomery RL, et al. Compensatory functions of histone deacetylase 1 (HDAC1) and HDAC2 regulate transcription and apoptosis during mouse oocyte development. Proc Natl Acad Sci USA. 2012;109(8):E481-E489.
11. Miller KM, Tjeertes JV, Coates J, et al. Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nat Struct Mol Biol. 2010;17(9): 1144-1151.
12. Moresi V, Carrer M, Grueter CE, et al. Histone deacetylases 1 and 2 regulate autophagy flux and skeletal muscle homeostasis in mice. Proc Natl Acad Sci USA. 2012;109(5):1649-1654.
13. Lagger G, O’Carroll D, Rembold M, et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J. 2002;21(11):2672-2681.
14. Grausenburger R, Bilic I, Boucheron N, et al. Conditional deletion of histone deacetylase 1 in T cells leads to enhanced airway inflammation and increased Th2 cytokine production. J Immunol. 2010;185(6):3489-3497.
15. Trivedi CM, Luo Y, Yin Z, et al. Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat Med. 2007;13(3):324-331.
16. Zimmermann S, Zimmermann S, Zimmermann S, et al. Reduced body size and decreased intestinal tumor rates in HDAC2-mutant mice. 2007;67(19): 9047–9054.
17. Guan J-S, Haggarty SJ, Giacometti E, et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature. 2009;459(7243): 55-60.
18. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006;6(1):38-51.
19. Brehm A, Miska EA, McCance DJ, et al. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature. 1998;391(6667):597-601.
20. Luo J, Su F, Chen D, et al. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature. 2000;408(6810):377-381.
21. Cismasiu VB, Adamo K, Gecewicz J, et al. BCL11B functionally associates with the NuRD complex in T lymphocytes to repress targeted promoter. Oncogene. 2005;24(45):6753-6764.
22. Guo H, Friedman AD. Phosphorylation of RUNX1 by cyclin-dependent kinase reduces direct interaction with HDAC1 and HDAC3. J Biol Chem. 2011;286(1):208-215.
23. Fischer A, Sananbenesi F, Mungenast A, et al. Targeting the correct HDAC(s) to treat cognitive disorders. Trends Pharmacol Sci. 2010;31(12): 605-617.
24. Christensen DP, Dahllöf M, Lundh M, et al. Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus. Mol Med. 2011; 17(5-6):378-390.
25. Wilting RH, Dannenberg J-H. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. Drug Resist Updat. 2012;15(1-2):21-38.
26. Archin NM, Liberty AL, Kashuba AD, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012; 487(7408):482-485.
27. Takahama Y, Ohishi K, Tokoro Y, et al. Functional competence of T cells in the absence of glycosylphosphatidylinositol-anchored proteins caused by T cell-specific disruption of the Pig-a gene. Eur J Immunol. 1998;28(7):2159-2166.
28. Uren AG, Kool J, Matentzoglu K, et al. Large-scale mutagenesis in p19(ARF)- and p53-deficient mice identifies cancer genes and their collaborative networks. Cell. 2008;133(4): 727-741.
29. de Jong J, de Ridder J, van der Weyden L, et al. Computational identification of insertional mutagenesis targets for cancer gene discovery. Nucleic Acids Res. 2011;39(15):e105.
30. Gutierrez A, Sanda T, Ma W, et al. Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. Blood. 2010;115(14):2845-2851.
31. Gaudet F, Hodgson JG, Eden A, et al. Induction of tumors in mice by genomic hypomethylation. Science. 2003;300(5618):489-492.
32. Aster JC, Blacklow SC, Pear WS. Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies. J Pathol. 2011;223(2):262-273.
33. Eischen CM, Weber JD, Roussel MF, et al. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 1999;13(20): 2658-2669.
34. Kamijo T, Zindy F, Roussel MF, et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell. 1997;91(5):649-659.
35. Baxter EW, Blyth K, Cameron ER, et al. Selection for loss of p53 function in T-cell lymphomagenesis is alleviated by Moloney murine leukemia virus infection in myc transgenic mice. J Virol. 2001; 75(20):9790-9798.
36. Guo X, Williams JG, Schug TT, et al. DYRK1A and DYRK3 promote cell survival through phosphorylation and activation of SIRT1. J Biol Chem. 2010;285(17):13223-13232.
37. van der Weyden L, Rust AG, McIntyre RE, et al. Jdp2 downregulates Trp53 transcription to promote leukaemogenesis in the context of Trp53 heterozygosity. Oncogene. 2013;32(3):397-402.
38. Kortlever RM, Brummelkamp TR, van Meeteren LA, et al. Suppression of the p53-dependent replicative senescence response by lysophosphatidic acid signaling. Mol Cancer Res. 2008;6(9):1452-1460.
39. Stewart M, Mackay N, Hanlon L, et al. Insertional mutagenesis reveals progression genes and checkpoints in MYC/Runx2 lymphomas. Cancer Res. 2007;67(11):5126-5133.
40. Taghavi P, Verhoeven E, Jacobs JJL, et al. In vitro genetic screen identifies a cooperative role for LPA signaling and c-Myc in cell transformation. Oncogene. 2008;27(54):6806-6816.
41. Taylor BS, DeCarolis PL, Angeles CV, et al. Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas. Cancer Discov. 2011; 1(7):587-597.
42. Kim H-S, Vassilopoulos A, Wang R-H, et al. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell. 2011;20(4):487-499.
43. Bhaskara S, Knutson SK, Jiang G, et al. Hdac3 is essential for the maintenance of chromatin structure and genome stability. Cancer Cell. 2010;18(5): 436-447.
44. Nikoloski G, Langemeijer SMC, Kuiper RP, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet. 2010; 42(8):665-667.
45. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424-2433.
46. Gutierrez A, Kentsis A, Sanda T, et al. The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia. Blood. 2011;118(15):4169-4173.
47. Grossmann V, Kern W, Harbich S, et al. Prognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemia. Haematologica. 2011;96(12):1874-1877.
48. Weichert W, Röske A, Gekeler V, et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol. 2008;9(2):139-148.
49. Lagger S, Meunier D, Mikula M, et al. Crucial function of histone deacetylase 1 for differentiation of teratomas in mice and humans. EMBO J. 2010;29(23): 3992-4007.